You are here

American Diabetes Association Issues Standards of Care Updates

New Medication Options for Patients With Type-2 Diabetes

The American Diabetes Association® (ADA) issued important updates to the 2019 Standards of Medical Care in Diabetes, in annotations as the Living Standards of Care. The changes focus on new metrics for continuous glucose monitoring (CGM) utilization and new medication options and recommendations for youth and adults with type-2 diabetes (T2D). Updates to Section 10, Cardiovascular Disease and Risk Management, have also been reviewed and approved by the American College of Cardiology. The Living Standards of Care is available online at Diabetes Care.

Two sections have been revised to incorporate the new international consensus report on continuous glucose monitoring (CGM) time-in-range goals; a new table has been added to help standardize CGM metrics for clinical care; and an example of an ambulatory glucose profile has been added to encourage consistency in CGM-data report interpretation.

Other revisions include the results of the Food and Drug Administration’s (FDA’s) approval of injectable liraglutide in pediatric patients with T2D who are 10 years of age and older. Liraglutide is the first non-insulin medication approved to treat T2D in the pediatric population since 2000.

Other updates reflect the results of the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial, which indicated that dulaglutide reduced the risk for nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death in adults with T2D with and without established cardiovascular disease.

Source: BioSpace, July 31, 2019

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs